While the detection of H3K27M histone mutations is used to classify these tumors as diffuse midline glioma, DMG H3K27-altered and defines these tumors as CNS WHO grade 4 tumors according to the WHO 2021 brain tumor classification [23], BRAF alterations (gene fusions or point mutations) arise in both low-grade gliomas (LGG) and a subset of high-grade gliomas (HGG) [6, 24]. The gene discussed is BRAF; the disease is central nervous system cancer.